Scarica l'app Stockscreener
40.75
1.21%
-0.50
Pre-mercato:
41.70
0.95
+2.33%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRNX Giù?
Forum
Previsione
Precedente Chiudi:
$41.25
Aprire:
$41.51
Volume 24 ore:
916.83K
Relative Volume:
0.83
Capitalizzazione di mercato:
$4.30B
Reddito:
$7.70M
Utile/perdita netta:
$-465.32M
Rapporto P/E:
-8.2413
EPS:
-4.9446
Flusso di cassa netto:
$-383.68M
1 W Prestazione:
+6.82%
1M Prestazione:
+9.45%
6M Prestazione:
-4.19%
1 anno Prestazione:
+21.10%
Intervallo 1D:
$40.06
$42.47
Intervallo di 1 settimana:
$37.35
$42.47
Portata 52W:
$25.83
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Nome
Crinetics Pharmaceuticals Inc
Settore
Industria
Telefono
858-450-6464
Indirizzo
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
40.75 | 4.35B | 7.70M | -465.32M | -383.68M | -4.9446 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-07-10 | Iniziato | Goldman | Neutral |
| 2025-03-25 | Iniziato | Stifel | Buy |
| 2025-02-11 | Iniziato | TD Cowen | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Peer Perform |
| 2025-01-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-01-16 | Iniziato | Morgan Stanley | Overweight |
| 2023-12-21 | Iniziato | Jefferies | Hold |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Iniziato | Oppenheimer | Outperform |
| 2023-04-24 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Robert W. Baird | Outperform |
| 2021-11-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-11-23 | Iniziato | Evercore ISI | Outperform |
| 2021-06-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Iniziato | ROTH Capital | Buy |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-13 | Iniziato | JP Morgan | Neutral |
| 2018-08-13 | Iniziato | Leerink Partners | Outperform |
| 2018-08-13 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie
Technical Reactions to CRNX Trends in Macro Strategies - Stock Traders Daily
[144] Crinetics Pharmaceuticals, Inc. SEC Filing - Stock Titan
The Bull Case For Crinetics Pharmaceuticals (CRNX) Could Change Following EU Nod For Oral Acromegaly Drug PALSONIFY - Yahoo Finance
Analysts estimate Crinetics Pharmaceuticals, Inc. (CRNX) to report a decline in earnings: What to look out for - MSN
Crinetics Pharmaceuticals (CRNX): Billionaire Tom Steyer Likes This Pharma Stock - Insider Monkey
Crinetics Pharmaceuticals Inc (HAM:6Z4) Valuation: Possible Value Trap, Think Twice - GuruFocus
Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Weekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA - RTTNews
Crinetics Pharmaceuticals (CRNX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Crinetics Pharmaceuticals Inc Stock Intrinsic Values | HAM:6Z4 - GuruFocus
Q3 2024 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Crinetics Pharmaceuticals Inc Stock Historical Valuations - GuruFocus
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q3 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q1 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Crinetics Pharmaceuticals Inc Stock Warning Signs - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Earnings Transcripts - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4)Valuation Measures & Financial Statistics - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Crinetics Pharmaceuticals Inc Stock Baskets - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock News, Headlines & Updates - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Who's Buying or Selling Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Today? - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Price, Trades & News - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Stock Price & 30 Year Financial Data - GuruFocus
Crinetics Pharmaceuticals Inc Stock Operating Data - GuruFocus
Crinetics Pharmaceuticals Inc (HAM:6Z4) Dividend - GuruFocus
Vanguard Capital Management holds 5.19% of Crinetics (NASDAQ: CRNX) - Stock Titan
Crinetics (NASDAQ: CRNX) details 2026 meeting, board votes and auditor change - Stock Titan
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
Crinetics Pharmaceuticals Files Marketing Application for Acromegaly Drug in Brazil - HarianBasis.co
Crinetics Pharmaceuticals (CRNX) is One of the Best Biotech Stocks to Buy, Here is Why - Insider Monkey
Q1 Earnings Estimate for CRNX Issued By Lifesci Capital - MarketBeat
Pictet Asset Management Holding SA Has $72.63 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
5 Best Biotech Stocks with Highest Upside Potential - Insider Monkey
CRNX Maintains Market Outperform Rating -- Price Target Raised t - GuruFocus
Crinetics Pharmaceuticals (NASDAQ:CRNX) Given New $97.00 Price Target at Citizens Jmp - MarketBeat
Citizens raises Crinetics stock price target on EU drug approval By Investing.com - Investing.com Canada
Crinetics receives EU approval for acromegaly drug Palsonify By Investing.com - Investing.com India
Crinetics (CRNX) Secures EU Approval for Palsonify in Acromegaly Treatment - GuruFocus
Crinetics receives EU approval for acromegaly drug Palsonify - Investing.com UK
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults - The Manila Times
Crinetics Pharmaceuticals Announces the European Commission - GlobeNewswire
Impax Asset Management Group plc Buys Shares of 275,000 Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Mixed Recent Share Performance - Sahm
Trading the Move, Not the Narrative: (CRNX) Edition - Stock Traders Daily
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer - GlobeNewswire Inc.
Crinetics (CRNX) Stock: Trading Guide (Range-Bound) 2026-04-15Stock Trading Network - Cổng thông tin điện tử tỉnh Tây Ninh
Crinetics Pharmaceuticals Inc Azioni (CRNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):